Abstract Body

HCV cirrhotics decompensate at 5-7% per year with development of varices, ascites, hepatic encephalopathy or synthetic dysfunction. All cirrhotics should be monitored for hepatocellular carcinoma (1-4% develop HCC per year). Ultrasonography is recommended every 6 months (estimated doubling time of HCC 136 days). Quadruple–phase computed tomography or MRI is used to confirm any abnormalities seen. Cirrhotics should undergo upper endoscopy to evaluate for varices. If Grade 2 or greater varices are found, primary prophylaxis with a non-selective beta blocker (propranolol or nadolol) should be initiated to decrease the heart rate by 10%. If beta blockers cannot be tolerated, then band ligation of varices is recommended. Transjugular intrahepatic portosystemic shunting (TIPS) promptly drops portal pressure.
All patients with ascites require diagnostic paracentesis to evaluate for portal hypertension and to exclude spontaneous bacterial peritonitis. Portal hypertension is suggested when serum to ascites albumin gradient is ≥1.1 mg/dL. Management of ascites includes sodium restriction (<2 g/day) and diuretics: spironolactone combined with furosemide (ratio of 40 mg furosemide: 100 mg spironolactone, increasing as needed). With progression, ascites becomes diuretic refractory and treatment usually requires large-volume paracentesis (LVP) or TIPS. For every liter of ascites removed, 50 cc of 25% salt poor albumin iv must be given. While TIPS is associated with greater transplant-free survival than LVP, it also has a much higher rate of hepatic encephalopathy.
The new all oral direct acting antiviral agents (DAA) for HCV have permanently changed the treatment landscape for patients with end stage HCV. The current AASLD/IDSA 2014 guidelines (http://www.hcvguidelines.org) recommend that patients with decompensated cirrhosis should have an experienced HCV treater and be referred for liver transplant evaluation. Recommended regimens for genotype 1 and 4 are daily fixed-dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) with RBV for 12 weeks in naïve patients, and 24 weeks in prior sofosbuvir failures. If RBV intolerant, daily fixed-dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) for 24 weeks is recommended. The regimen for Genotype 2 and 3 HCV patients with decompensated cirrhosis is daily sofosbuvir (400 mg) and weight-based RBV for up to 48 weeks. However, these patients may have lower SVR and ongoing decompensation, so careful monitoring is required.